MX9701894A - Quinoxalinadionas antagonistas del receptor n-metil-d-aspartato. - Google Patents
Quinoxalinadionas antagonistas del receptor n-metil-d-aspartato.Info
- Publication number
- MX9701894A MX9701894A MX9701894A MX9701894A MX9701894A MX 9701894 A MX9701894 A MX 9701894A MX 9701894 A MX9701894 A MX 9701894A MX 9701894 A MX9701894 A MX 9701894A MX 9701894 A MX9701894 A MX 9701894A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- ch2ch3
- piperazine
- independently
- quinoxalinedione
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical compound C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 title 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000002785 azepinyl group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Compuestos de la formula (I), en la que R1 y R2 son cada uno independientemente F, Cl, Br, CH3, CH2CH3 o CF3; R3 es H, CH3, o CH2CH3; y X es un grupo heterociclico que contiene hasta cuatro átomos de N, unido por un átomo de nitrogeno; estando dicho grupo opcionalmente condensado con benceno y/o sustituido por alquilo C1-C6, cicloalquilo C3-C6 o alquilo C1-C4 sustituido por fenilo o piridilo, o R4 y R5 están unidos para formar junto con el átomo de nitrogeno al que están unidos, un grupo pirrolidina, piperidina, piperazina, N-(alquilo C1-C4) piperazina, morfolina o azepina, y sus sales farmacéuticamente aceptables; son antagonistas de NMDA de utilidad en el tratamiento de trastornos neurodegenerativos agudos, por ejemplo, derivados de ataque apopléjico o daño craneal traumático y en trastornos neurologicos cronicos, por ejemplo, demencia senil y enfermedad de Alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9418443A GB9418443D0 (en) | 1994-09-13 | 1994-09-13 | Therapeutic agents |
| PCT/EP1995/003483 WO1996008485A1 (en) | 1994-09-13 | 1995-09-01 | Quinoxalinedione nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9701894A true MX9701894A (es) | 1997-06-28 |
Family
ID=10761258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9701894A MX9701894A (es) | 1994-09-13 | 1995-09-01 | Quinoxalinadionas antagonistas del receptor n-metil-d-aspartato. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5783572A (es) |
| EP (1) | EP0781279B1 (es) |
| JP (1) | JP2898097B2 (es) |
| AT (1) | ATE202099T1 (es) |
| CA (1) | CA2199845C (es) |
| DE (1) | DE69521323T2 (es) |
| DK (1) | DK0781279T3 (es) |
| ES (1) | ES2158126T3 (es) |
| FI (1) | FI113471B (es) |
| GB (1) | GB9418443D0 (es) |
| GR (1) | GR3036270T3 (es) |
| MX (1) | MX9701894A (es) |
| PT (1) | PT781279E (es) |
| WO (1) | WO1996008485A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110911A (en) * | 1995-06-07 | 2000-08-29 | Warner-Lambert Company | Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| US5874426A (en) * | 1995-06-07 | 1999-02-23 | Warner-Lambert Company | Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| MY132385A (en) * | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
| GB9605027D0 (en) | 1996-03-09 | 1996-05-08 | Pfizer Ltd | Quinoxalinediones |
| AU5367598A (en) * | 1996-11-25 | 1998-06-22 | Warner-Lambert Company | Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| US6172065B1 (en) | 1997-03-04 | 2001-01-09 | Warner-Lambert Company | Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| US6340758B1 (en) * | 1997-05-16 | 2002-01-22 | Warner-Lambert Company | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
| TW526195B (en) | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
| DE19936521A1 (de) * | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate |
| JP2005506292A (ja) * | 2001-03-08 | 2005-03-03 | エモリー ユニバーシティ | ｐＨに依存するＮＭＤＡレセプターアンタゴニスト |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| US20060142186A1 (en) * | 2004-12-23 | 2006-06-29 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| EP2117540A1 (en) | 2007-03-01 | 2009-11-18 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| CN103058957A (zh) | 2007-06-29 | 2013-04-24 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| BR112013014484A2 (pt) * | 2010-12-13 | 2016-07-19 | Viamet Pharmaceuticals Inc | compostos inibidores de metaloenzimas |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| DE102015011861B4 (de) | 2015-09-10 | 2018-03-01 | Rudolf Schindler | Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
| GB8827822D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| DK715888D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
| DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
| AU672617B2 (en) * | 1992-06-22 | 1996-10-10 | Regents Of The University Of California, The | Glycine receptor antagonists and the use thereof |
-
1994
- 1994-09-13 GB GB9418443A patent/GB9418443D0/en active Pending
-
1995
- 1995-09-01 MX MX9701894A patent/MX9701894A/es not_active IP Right Cessation
- 1995-09-01 ES ES95931989T patent/ES2158126T3/es not_active Expired - Lifetime
- 1995-09-01 US US08/793,896 patent/US5783572A/en not_active Expired - Fee Related
- 1995-09-01 PT PT95931989T patent/PT781279E/pt unknown
- 1995-09-01 JP JP8509872A patent/JP2898097B2/ja not_active Expired - Fee Related
- 1995-09-01 DK DK95931989T patent/DK0781279T3/da active
- 1995-09-01 CA CA002199845A patent/CA2199845C/en not_active Expired - Fee Related
- 1995-09-01 AT AT95931989T patent/ATE202099T1/de not_active IP Right Cessation
- 1995-09-01 DE DE69521323T patent/DE69521323T2/de not_active Expired - Fee Related
- 1995-09-01 WO PCT/EP1995/003483 patent/WO1996008485A1/en active IP Right Grant
- 1995-09-01 EP EP95931989A patent/EP0781279B1/en not_active Expired - Lifetime
-
1997
- 1997-03-12 FI FI971026A patent/FI113471B/fi active
-
2001
- 2001-07-24 GR GR20010401119T patent/GR3036270T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GR3036270T3 (en) | 2001-10-31 |
| FI113471B (fi) | 2004-04-30 |
| EP0781279B1 (en) | 2001-06-13 |
| DE69521323D1 (de) | 2001-07-19 |
| GB9418443D0 (en) | 1994-11-02 |
| ES2158126T3 (es) | 2001-09-01 |
| FI971026A0 (fi) | 1997-03-12 |
| DE69521323T2 (de) | 2001-09-20 |
| US5783572A (en) | 1998-07-21 |
| WO1996008485A1 (en) | 1996-03-21 |
| JPH09511523A (ja) | 1997-11-18 |
| CA2199845A1 (en) | 1996-03-21 |
| ATE202099T1 (de) | 2001-06-15 |
| EP0781279A1 (en) | 1997-07-02 |
| CA2199845C (en) | 2000-08-01 |
| JP2898097B2 (ja) | 1999-05-31 |
| DK0781279T3 (da) | 2001-09-03 |
| PT781279E (pt) | 2001-09-28 |
| FI971026A (fi) | 1997-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9701894A (es) | Quinoxalinadionas antagonistas del receptor n-metil-d-aspartato. | |
| AU648424B2 (en) | Substituted cyclopropylamino-1,3,5-triazines | |
| NZ508910A (en) | Di-substituted piperazine or piperidine derivatives useful as muscarinic antagonists | |
| ATE170523T1 (de) | Piperidinderivate mit anxiolytischer wirkung | |
| TW369526B (en) | Diazabicyclic neurokinin antagonists | |
| HUT60733A (en) | Process for producing new n-(4-piperidinyl)-(dihydrobenzofuran or dihydro-2h-benzopyran)-carboxamide derivatives and pharmaceutical compositions comprising such compounds | |
| NZ507119A (en) | 1-[(4-Piperidinyl)methyl]-4-piperidine derivatives useful for treating gastrointestinal disorders | |
| IL189069A0 (en) | Piperidine and piperazine derivatives as p2x3 antagonists | |
| NZ334017A (en) | 1,4-di-substituted piperidines and use in combination with acetylcholinesterase inhibitors for treating cognitive disorders | |
| NZ331060A (en) | Quinoxalinediones, preparation and pharmaceutical compositions thereof | |
| NZ331613A (en) | Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives | |
| NZ333513A (en) | 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists | |
| US5338738A (en) | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines | |
| GB9000301D0 (en) | Piperidine & pyrrolidine derivatives | |
| KR900014408A (ko) | 신규 1h,3h-피롤로 [1,2-c] 티아졸-7-카르복스 아미드 유도체, 그 제조 및 상기 유도체를 함유하는 제약학적 조성물 | |
| ATE138067T1 (de) | 1,2,4-triazolo(1,5-a>pyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung | |
| EP0728748A4 (en) | NEW BENZODIAZEPINE DERIVATIVE | |
| ATE284401T1 (de) | Verknüpfte polycyclische heterocyclische verbindungen | |
| BG60066B2 (bg) | Метод за получаване на 4-/3-/4-оксотиазолидин//бутиниламин | |
| EP0798304A4 (en) | DRUGS AGAINST TRHOMBOCYTOPENIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: PFIZER IRELAND PHARMACEUTICALS |
|
| MM | Annulment or lapse due to non-payment of fees |